CEO Executive AssistantPost-market surveillance is a critical but often underemphasized function in pharmaceutical organizations. Once a product is approved and on the market, the work of monitoring its real-world safety and effectiveness continues indefinitely. Adverse event collection, safety signal detection, periodic safety update reports, risk management plan implementation, and post-approval study commitments all require ongoing operational management.
For pharma CEOs, post-market surveillance is a function with profound accountability implications that must be thoroughly delegated operationally while remaining a CEO-level priority from a patient safety and regulatory compliance perspective.
Why Post-Market Surveillance Delegation Is Critical
Post-market surveillance failures have ended pharmaceutical company careers and caused serious patient harm. When safety signals are not detected, investigated, or communicated appropriately, the consequences range from regulatory sanctions to product withdrawals to litigation.
This makes post-market surveillance one of the most important functions to delegate correctly: to the right people, with the right resources, with the right governance, and with appropriate CEO oversight.
The CEO’s Post-Market Surveillance Role
Patient safety accountability. The CEO is ultimately accountable for the organization’s patient safety record. This accountability drives the CEO’s responsibility to ensure post-market surveillance is adequately resourced, appropriately governed, and functioning effectively.
Major safety actions. Product recalls, voluntary market withdrawals, Dear Healthcare Provider letters, and Urgent Safety Measures require CEO awareness and in some cases CEO decision authority.
Regulatory accountability for safety communications. When regulatory agencies communicate concerns about marketed product safety, the CEO leads the organizational response.
Safety culture. The CEO sets the organizational culture regarding patient safety: that regulatory compliance is a floor, not a ceiling, and that patient safety concerns are addressed aggressively and transparently.
Pharmacovigilance investment decisions. Staffing the PV function, investing in safety data systems, and funding post-approval commitments require CEO-level budget commitment.
Post-Market Surveillance Delegation Framework
To the Head of Pharmacovigilance or Chief Safety Officer
Adverse event collection and processing. Managing the intake, coding, and reporting of adverse event reports from all sources (spontaneous reports, literature, clinical trials, regulatory authority reports) is a pharmacovigilance operations function.
Expedited safety reporting. Preparing and submitting 15-day reports, expedited ICSRs, and other time-sensitive safety reports to regulatory agencies is a PV operations responsibility.
Periodic safety update reports. Preparing PSURs, PBRERs, and other periodic safety reports for submission to regulatory agencies is a PV function.
Signal detection and evaluation. Conducting disproportionality analyses, evaluating safety signals from internal and external data sources, and managing the signal evaluation process are PV analytics functions.
Risk management plan implementation. Implementing Risk Management Plans and REMS programs, including required educational programs, prescriber certification, and pharmacy programs, is a safety and medical affairs function.
Post-approval study management. Managing post-approval safety studies committed to regulatory agencies during product approval is a PV and clinical operations function.
Literature monitoring. Continuously monitoring scientific literature for case reports, case series, or studies with safety implications is a PV literature surveillance function.
To the Medical Affairs and Clinical Safety Teams
Safety narrative development. When safety signals require narrative assessment and regulatory response, the medical affairs and clinical safety teams develop the clinical evaluation.
Label update coordination. When post-market surveillance identifies new safety information requiring label updates, the regulatory affairs team manages the update process with PV and medical input.
To Quality and Compliance
PV quality system. Maintaining the pharmacovigilance quality system, conducting PV audits, and managing PV SOPs are quality and PV functions.
Regulatory inspection preparation for PV. Preparing for pharmacovigilance inspections is a PV and quality function.
Building Post-Market Surveillance Delegation Infrastructure
Safety Case Processing System
A validated safety database (Argus, ARISg, Oracle) is foundational to efficient post-market surveillance. The PV team manages the system; the CEO never interacts with the database directly but relies on summary reporting from it.
Safety Signal Review Committee
A formal safety signal review committee, including medical officers, pharmacovigilance scientists, and clinical safety reviewers, evaluates signals and determines appropriate action. The CEO may be briefed on significant signals but does not participate in routine signal evaluation.
CEO Safety Dashboard
A quarterly safety dashboard for the CEO covers:
- Adverse event reporting volumes and trends
- Active safety signals under evaluation
- Regulatory safety commitments status
- Recent significant safety actions by competitors or in the therapeutic area
- PV compliance indicators
Escalation Protocol for Safety Events
Events requiring immediate CEO notification:
- Detection of a serious unexpected safety signal
- Any anticipated product recall or market withdrawal
- Regulatory authority request for urgent safety meeting
- Significant failure in PV reporting compliance
- Patient death or serious injury potentially attributable to product quality failure
For pharma CEOs managing post-market surveillance alongside clinical and regulatory operations, delegation guide for pharma CEO: regulatory affairs covers the regulatory complement to PV management.
Pharmacovigilance delegation is closely related to the broader quality and safety delegation frameworks in delegation framework for pharma CEO: quality assurance.
Conclusion
Post-market surveillance is a safety-critical function that must be properly resourced, appropriately governed, and thoroughly delegated while remaining a CEO accountability priority. The pharma CEO who invests in strong pharmacovigilance leadership, builds robust PV systems, and maintains accountability through governance and regular reporting protects patients, the organization, and the CEO’s own leadership legacy.
Fund the function. Trust the team. Stay accountable for the outcomes.
For pharmaceutical pharmacovigilance and post-market safety insights, visit McKinsey.com/industries/life-sciences.
Related Reading
For further context, explore Pharma CEO Delegation for Drug Pipeline Management and Pharma CEO Delegation for Launch Teams.